GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Actuate Therapeutics Inc.
The stock of Actuate, an oncology biotech company, reflects the potential of its lead drug candidate. Its price trajectory is highly speculative and depends on clinical trial results and investor confidence in the drug's novel mechanism of action.
Share prices of companies in the market segment - Cancer cure
Actuate Therapeutics, Inc. is a biopharmaceutical company developing GSK-3Ξ² inhibitors, a new class of targeted therapy for the treatment of oncology diseases. We classify the company in the Cancer Treatment segment, where it is working on an innovative approach. The chart below shows the overall dynamics of this high-risk but promising sector.
Broad Market Index - GURU.Markets
Actuate Therapeutics is an oncology company developing drugs that target the signaling pathways responsible for cancer cell growth and survival. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ACTU - Daily change in the company's share price Actuate Therapeutics Inc.
Shares of Actuate Therapeutics, an oncology company, exhibit high volatility, as measured by change_co. This reflects sensitivity to news about clinical trials. This metric is important for biotech sector analysis on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Cancer cure
Actuate Therapeutics, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with ACTU's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Actuate Therapeutics is a biotech company developing cancer treatments. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Actuate Therapeutics Inc.
Actuate Therapeutics, Inc.'s year-over-year performance is a story of developing a new class of cancer drugs. Its 12-month market cap is entirely dependent on the progress of its lead candidate in clinical trials. Positive data could confirm the potential of its unique approach to targeted therapy.
Annual dynamics of market capitalization of the market segment - Cancer cure
Actuate, a private biotech company, develops drugs to treat cancer. Its growth depends on success in clinical trials. Its valuation dynamics reflect investors' confidence in its scientific platform, potentially outperforming the overall pharmaceutical sector, but with higher risks.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Actuate Therapeutics is a clinical-stage biotech whose fate since its IPO has depended on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Actuate Therapeutics Inc.
Actuate Therapeutics, Inc. (Cancer Cure) is focused on oncology. Monthly market capitalization dynamics (Perf\_Month\_Co) reflect development cycles, where each clinical trial announcement or conference data presentation can trigger significant mid-term price movements.
Monthly dynamics of market capitalization of the market segment - Cancer cure
This chart reflects the dynamics of the biotech sector, particularly in oncology. For Actuate, an early-stage company, this is the backdrop. Its volatile movements demonstrate how investor expectations surrounding breakthroughs in cancer treatments are impacting the entire industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Actuate Therapeutics is a clinical-stage biotech company developing cancer treatments. Its value depends almost entirely on the results of clinical trials. The broader market has little impact on Actuate's stock; its fate is decided in labs and clinics, which can lead to sharp movements counter to any market trend.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Actuate Therapeutics Inc.
Actuate Therapeutics is a clinical-stage oncology company. Its weekly stock price, like that of other biotechs, is entirely dependent on news about the progress of clinical trials, which can cause sharp price fluctuations in either direction.
Weekly dynamics of market capitalization of the market segment - Cancer cure
Actuate Therapeutics is an oncology company developing drugs to treat pancreatic cancer and other difficult-to-treat tumors. This is a high-risk, high-reward field. The chart clearly shows how disconnected its performance is from the market and dependent on lab news.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Actuate is an oncology company operating in a promising field. Its shares are a pure bet on a scientific breakthrough. The chart clearly shows their extreme volatility and complete dependence on news about clinical trials, not the market.
Market capitalization of the company, segment and market as a whole
ACTU - Market capitalization of the company Actuate Therapeutics Inc.
The market capitalization chart of Actuate Therapeutics, a clinical-stage oncology company, reflects investors' faith in its novel drug mechanism of action. Its valuation is speculative and depends entirely on the success of its clinical trials. Any new data could cause sharp price movements.
ACTU - Share of the company's market capitalization Actuate Therapeutics Inc. within the market segment - Cancer cure
Actuate Therapeutics is a clinical-stage oncology company developing a new class of cancer drugs. Its market share currently reflects only the potential of its research. Its market cap is a venture bet on the success of its clinical trials and the promise of new ways to fight cancer.
Market capitalization of the market segment - Cancer cure
Here's a chart showing the biotech sector's market capitalization. Actuate Therapeutics is a precision oncology company. Its developments target the GSK-3Ξ² pathway, which plays a role in many types of cancer. The potential of this market is enormous, and Actuate is committed to proving the effectiveness of its unique approach.
Market capitalization of all companies included in a broad market index - GURU.Markets
Actuate Therapeutics is an oncology company developing a new class of drugs that inhibit GSK-3Ξ², a key enzyme in many cancers. Its market cap is a bet on this new scientific approach. The chart below shows the weightings of companies attacking cancer from a new angle.
Book value capitalization of the company, segment and market as a whole
ACTU - Book value capitalization of the company Actuate Therapeutics Inc.
Actuate Therapeutics' book value is its equity and the intellectual property it holds for its drug, which inhibits GSK-3Ξ² for the treatment of cancer. The chart is a financial timeline of the biotech company as it advances its lead candidate through clinical trials, where each stage requires significant investment, forming its intangible asset.
ACTU - Share of the company's book capitalization Actuate Therapeutics Inc. within the market segment - Cancer cure
Actuate Therapeutics develops drugs to treat cancer. The chart shows its share of actual R&D assets. These are its laboratories where they study new mechanisms of action for drugs capable of stopping the growth of tumors resistant to other therapies.
Market segment balance sheet capitalization - Cancer cure
Actuate Therapeutics is a biotech company whose value is locked into its development pipeline. Its business is capital-light. The chart below reflects the capital intensity of the pharmaceutical sector, which underscores its R&D-focused model.
Book value of all companies included in the broad market index - GURU.Markets
Actuate Therapeutics is an oncology company developing GSK-3Ξ² inhibitors, a new class of targeted therapy. Its assets are its clinical development pipeline. A modest stake in BCap_All is a financial resource aimed at testing a promising hypothesis for cancer treatment.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Actuate Therapeutics Inc.
Actuate Therapeutics is an oncology biotech. Its entire market capitalization is a premium to its cash flow. This premium is a bet on the success of its clinical trials.
Market to book capitalization ratio in a market segment - Cancer cure
Actuate Therapeutics is an oncology company developing new treatments. Its value is based almost entirely on the potential of its lead drug. The chart shows the huge premium to book value that investors are paying for the hope of clinical success.
Market to book capitalization ratio for the market as a whole
Actuate Therapeutics is an oncology company developing drugs to treat pancreatic cancer and other difficult-to-treat tumors. Its value lies in its scientific potential. This chart shows the market premium for technologies targeting the most complex medical problems.
Debts of the company, segment and market as a whole
ACTU - Company debts Actuate Therapeutics Inc.
Actuate Therapeutics, an oncology company developing GSK-3Ξ² inhibitors, is raising capital to fund its clinical trials. The debt burden reflects the cost of advancing its lead candidate through various phases of clinical trials for pancreatic cancer and other solid tumors, a costly process.
Market segment debts - Cancer cure
Actuate Therapeutics is a clinical-stage biotech company developing cancer therapies. Funding is a key factor in success in this field. This chart shows whether the company is pursuing the traditional biotech equity financing model to advance its oncology drugs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Actuate Therapeutics Inc.
Actuate Therapeutics is an oncology company developing new cancer treatments. Its survival and success depend on its ability to fund lengthy and expensive clinical trials. This chart shows the company's reliance on debt, which is a direct indicator of its financial risk and margin of safety.
Market segment debt to market segment book capitalization - Cancer cure
Actuate Therapeutics is an oncology company developing drugs targeting GSK-3Ξ², a key regulator of many cancer cell signaling pathways. This chart shows debt trends in their sector. It helps assess how the company finances its innovative research and how its financial model compares to other biotech startups.
Debt to book value of all companies in the market
Actuate Therapeutics is an oncology company in clinical development. Its survival depends entirely on its ability to raise equity capital to fund expensive and time-consuming research. This graph of the total debt burden in the economy clearly demonstrates that Actuate's financial model is not about debt management, but about managing investor expectations and scientific risks.
P/E of the company, segment and market as a whole
P/E - Actuate Therapeutics Inc.
Actuate Therapeutics is an oncology company developing drugs that target a specific enzyme associated with cancer cell growth. This chart reflects investor expectations for its research program. The valuation is based on clinical development potential, not current financial performance.
P/E of the market segment - Cancer cure
This chart shows the average valuation for biotech companies, providing context for Actuate Therapeutics. It reflects generally high valuations based on hopes for a breakthrough. Comparisons help understand whether Actuate's targeted cancer therapy is considered more or less promising than dozens of other oncology biotechs.
P/E of the market as a whole
Actuate Therapeutics is a clinical-stage oncology company developing drugs targeting novel molecular targets. Its value is entirely dependent on future research results. This chart, which tracks overall biotech sentiment, serves as a barometer for Actuate's availability of capital to continue its scientific work.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Actuate Therapeutics Inc.
Actuate Therapeutics is a clinical-stage oncology company developing drugs that target a specific signaling pathway in cancer cells. This graph shows the speculative expectations for its scientific approach. The valuation depends entirely on the results of clinical trials and the potential of its therapy for treating difficult-to-treat cancers.
%20P%2FE%20Actuate%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Actuate-Therapeutics-Inc.&v=1772661406735 "Chart of the company's future (projected) P/E Actuate Therapeutics Inc.")
Future (projected) P/E of the market segment - Cancer cure
Actuate Therapeutics is a biopharmaceutical company developing drugs to treat cancer and inflammatory diseases. This chart reflects investor expectations for the company's profitability relative to the sector. It allows one to assess the market's confidence in its scientific approach and potential for developing new targeted therapies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772661406747 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
Actuate Therapeutics is a clinical-stage oncology company developing drugs that target novel signaling pathways in cancer cells. For a biotech company like Actuate, this market risk appetite curve is vital. Raising capital for costly clinical trials directly depends on investors' confidence in their scientific approach and potential.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772661406782 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Actuate Therapeutics Inc.
Actuate Therapeutics is an oncology company developing drugs targeting GSK-3Ξ², a key enzyme involved in the development of many types of cancer. This chart shows the company's financial performance during the clinical trials of this promising approach.
Profit of companies in the market segment - Cancer cure
Actuate Therapeutics is an oncology company developing drugs that target key signaling pathways in cancer cells. This chart shows profitability in the oncology sector. For ACTU, this reflects the search for new targets for cancer treatment. Their scientific approach focuses on the mechanisms that allow tumors to grow and survive.
Overall market profit
Actuate Therapeutics is a clinical-stage oncology company developing drugs that inhibit a key enzyme involved in tumor growth. This targeted therapy has the potential to treat various types of cancer. The company's success depends on research results. This gross margin graph is not related to its scientific prospects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Actuate Therapeutics Inc.
Actuate Therapeutics is a clinical-stage oncology company developing a new class of drugs targeting a key signaling pathway in cancer cells. The revenue projections presented here are speculative and reflect expectations for the success of its lead candidate in clinical trials.
%20profit%20of%20the%20company%20Actuate%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Actuate-Therapeutics-Inc.&v=1772661406888 "Graph of future (projected) profit of the company Actuate Therapeutics Inc.")
Future (predicted) profit of companies in the market segment - Cancer cure
Actuate Therapeutics is an oncology company developing drugs that target pathways responsible for cancer cell growth and survival. The company's revenue forecast depends on the success of its clinical programs. This chart reflects analysts' collective belief that new approaches to targeted therapy will offer solutions for difficult-to-treat cancers.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772661406897 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
Actuate Therapeutics is a clinical-stage oncology company. Its future depends entirely on the success of its research and development. The overall market profit forecasts reflected here form the investment backdrop, which determines the ability of such companies to attract significant capital for costly trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772661406932 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Actuate Therapeutics Inc.
Actuate Therapeutics is an oncology company developing drugs that target signaling pathways that enable cancer cells to survive. This chart shows a high speculative valuation. Investors are betting on its innovative scientific approach and the potential to create a new class of cancer drugs.
P/S market segment - Cancer cure
Actuate Therapeutics is an oncology company developing drugs that target key signaling pathways responsible for cancer cell growth and survival. This chart reflects the average revenue estimate in the biotech sector, providing insight into investor expectations for Actuate's scientific platform and clinical development.
P/S of the market as a whole
Actuate Therapeutics is a clinical-stage oncology company developing drugs that target a key enzyme involved in tumor growth. The company's success is entirely dependent on the results of clinical trials. This chart provides a general market backdrop for assessing investor sentiment toward high-risk biotech companies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Actuate Therapeutics Inc.
Actuate Therapeutics is an oncology company developing drugs that target key cancer cell survival pathways. This chart shows how the market values ββthe company based on its future revenue potential. It reflects expectations for the success of its developments in clinical trials.
%20P%2FS%20Actuate%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Actuate-Therapeutics-Inc.&v=1772661406990 "The graph of the company's future (projected) P/S Actuate Therapeutics Inc.")
Future (projected) P/S of the market segment - Cancer cure
Actuate Therapeutics is an oncology company developing drugs that target key pathways in cancer cell survival. Its approach may be effective in treating a variety of tumor types. This chart reflects investors' confidence in its scientific approach and the potential of its developments.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772661406998 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
Actuate Therapeutics is a clinical-stage oncology company developing a new class of drugs. Their future depends entirely on the success of clinical trials and raising capital. This market optimism curve is vital for the ACTU. Funding for such risky projects is only possible when investors are optimistic and willing to wait for a scientific breakthrough.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772661407000 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Actuate Therapeutics Inc.
Actuate Therapeutics is a clinical-stage biotechnology company focused on developing innovative cancer treatments. Currently, the company has no commercial products and no revenue. This timeline will show whether its scientific approach can lead to the development of sought-after oncology drugs.
Sales of companies in the market segment - Cancer cure
Actuate Therapeutics is a clinical-stage biopharmaceutical company developing a new class of drugs targeting a key enzyme involved in the growth of many types of cancer. Being in the research stage, the company has not yet generated commercial revenue, but its drugs are undergoing patient trials.
Overall market sales
Actuate Therapeutics is an oncology company developing drugs that target a key biological pathway involved in the growth and survival of cancer cells. Its research may lead to new treatments for various types of cancer. This total revenue chart includes the healthcare sector, where ACTU is at the forefront of scientific research in the fight against cancer.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Actuate Therapeutics Inc.
Actuate Therapeutics is an oncology company developing drugs that inhibit a key enzyme involved in cancer cell growth. This chart reflects analysts' confidence in the potential of this new approach and its applicability across various cancer types.
%20sales%20of%20the%20company%20Actuate%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Actuate-Therapeutics-Inc.&v=1772661407016 "Schedule of future (projected) sales of the company Actuate Therapeutics Inc.")
Future (projected) sales of companies in the market segment - Cancer cure
Actuate Therapeutics is an oncology company developing drugs targeting a novel signaling pathway that plays a key role in the growth of many cancers. This chart shows forecasts for the entire targeted cancer therapy market. It reflects expectations for the emergence of innovative drugs that can help patients who do not respond to existing treatments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772661407023 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
Actuate Therapeutics, an oncology company, sees this chart as a reflection of the investment climate in biotech. The stable economic growth projected here provides the capital needed to conduct clinical trials of innovative drugs. This capital is critical for the development of new cancer treatments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772661407042 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Actuate Therapeutics Inc.
Actuate Therapeutics is a clinical-stage oncology company developing cancer treatments. Its financial performance is focused on research and development expenses. This chart shows not current profit, but rather the capital burn rate, a key metric for biotech companies seeking to bring a new product to market.
Market segment marginality - Cancer cure
Actuate Therapeutics is an oncology company developing a new class of drugs that target a key pathway in cancer cell survival. This graph reflects the potential of its innovative approach. Future high operating income will confirm the clinical efficacy and demand for its therapy.
Market marginality as a whole
Actuate Therapeutics is a clinical-stage oncology company. Its value and future depend entirely on the success of its drugs in clinical trials. This overall market return chart is completely unrelated to the world of biotech research, where science, data, and regulatory decisions rule supreme.
Employees in the company, segment and market as a whole
Number of employees in the company Actuate Therapeutics Inc.
Actuate Therapeutics is a clinical-stage oncology company developing a new class of drugs that target a key signaling pathway in cancer cells. This graph shows a small team of scientists conducting clinical trials of their lead candidate for the treatment of pancreatic cancer and other difficult-to-treat tumors.
Share of the company's employees Actuate Therapeutics Inc. within the market segment - Cancer cure
Actuate Therapeutics is a clinical-stage oncology company developing a new generation of targeted therapies. Clinical trials and research require a growing team of scientists and physicians. This graph demonstrates its potential and growing importance in the development of innovative cancer treatments.
Number of employees in the market segment - Cancer cure
Actuate Therapeutics is an oncology company developing drugs that target the signaling pathways that enable cancer cells to survive and grow. This graphic shows a team of scientists working to identify new vulnerabilities in cancer cells to create more effective treatments for patients who have failed existing therapies.
Number of employees in the market as a whole
Actuate Therapeutics, Inc. is an oncology company developing inhibitors for cancer treatment. Their research-intensive business requires significant investment. The overall economic climate, as measured by employment trends, creates the conditions for such financing. A growing market attracts capital to the biotech sector, allowing Actuate to advance its clinical programs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Actuate Therapeutics Inc. (ACTU)
Actuate Therapeutics, Inc. is a clinical-stage oncology company. This chart is their assessment of scientific potential. Astronomical market capitalization per employee is typical for biotech companies whose technology promises a breakthrough in treatment. The market is investing in a future in which a small team of scientists will create a blockbuster drug.
%20of%20the%20company%20Actuate%20Therapeutics%20Inc.%20(ACTU)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Actuate-Therapeutics-Inc.-ACTU&v=1772661407139 "Chart of market capitalization per employee (in thousands of dollars) of the company Actuate Therapeutics Inc. (ACTU)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
Actuate Therapeutics is an oncology company developing inhibitors for cancer treatment. Its market cap is based on the potential of its lead drug candidate. This chart shows how investors value its scientific innovation per employee, an important metric for clinical-stage biotech companies.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772661407144 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
Actuate Therapeutics is an oncology company developing drugs that target a novel signaling pathway in cancer cells. For a clinical-stage biotech, this metric reflects the potential of its innovative science. A high valuation per employee reflects investors' belief that its approach can lead to the creation of a new class of drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772661407145 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Actuate Therapeutics Inc. (ACTU)
Actuate Therapeutics is a clinical-stage biotech company developing targeted cancer treatments. This graph is negative. The company has no product revenue. Its small staff of scientists is dedicated to conducting clinical trials. Each employee represents an investment in the technology.
%20Chart%20Actuate%20Therapeutics%20Inc.%20(ACTU)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Actuate-Therapeutics-Inc.-ACTU&v=1772661407151 "Company Profit Per Employee (in thousands of dollars) Chart Actuate Therapeutics Inc. (ACTU)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
Actuate Therapeutics is a clinical-stage oncology company developing GSK-3 inhibitors, a new class of drugs for the treatment of cancer, including pancreatic cancer. This chart represents an industry benchmark. For biotech R&D companies, it serves as a benchmark, demonstrating the potential profitability the sector aspires to achieve if their innovative treatment approach is successful.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772661407153 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
Actuate Therapeutics is a clinical-stage biotech company focused on developing cancer treatments (including pancreatic cancer) by inhibiting a specific enzyme (GSK-3). This is R&D. The chart shows the R&D investment (negative return) per scientist working on this targeted therapy.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772661407162 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Actuate Therapeutics Inc. (ACTU)
Actuate Therapeutics is an oncology company in clinical development. This graph reflects the path from science to commercialization. Potentially high revenue per employee in the future will result from the successful launch of its targeted therapies, which will convert R&D investments into actual sales revenue.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Actuate-Therapeutics-Inc.-ACTU&v=1772661407168 "Sales chart per company employee Actuate Therapeutics Inc. (ACTU)")
Sales per employee in the market segment - Cancer cure
Actuate Therapeutics (ACTU) is a clinical-stage biotech developing cancer therapies. They have no commercial revenue. This chart reflects their R&D stage: their research staff is focused on research, resulting in zero revenue per employee compared to the industry average, which is dominated by blockbusters.
Sales per employee for the market as a whole
Actuate Therapeutics is a biotech company developing innovative drugs for the treatment of cancer (specifically pancreatic cancer). It's a pure R&D company. This graph likely shows zero revenue, as their research team is in clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Actuate Therapeutics Inc. (ACTU)
Actuate Therapeutics (ACTU) is a clinical-stage biotech developing cancer drugs, specifically GSK-3 inhibitors. This chart shows bearish bets. The high short interest reflects investor skepticism about their scientific target (GSK-3), which has historically been challenging to develop, or concerns about early-stage drug trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Actuate-Therapeutics-Inc.-ACTU&v=1772661407195 "Short Shares Chart for the Company Actuate Therapeutics Inc. (ACTU)")
Shares shorted by market segment - Cancer cure
Actuate (ACTU) is an oncology company developing a targeted therapy that targets a specific enzyme (GSK-3Ξ²) involved in cancer cell growth. This chart illustrates the general skepticism in the biotech sector, reflecting investor doubts about the success of clinical trials in this niche market.
Shares shorted by the overall market
Actuate Therapeutics (ACTU) is a clinical-stage oncology biotech. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing ACTU will be unable to raise funds for R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Actuate Therapeutics Inc. (ACTU)
Actuate Therapeutics is a clinical-stage biotech company working in oncology. This chart measures pure speculative hope. It shows when the stock is "overbought" on the slightest positive signal from the lab or "oversold" amid a long R&D cycle.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Actuate-Therapeutics-Inc.-ACTU&v=1772661407300 "RSI 14 indicator chart for the company's stock Actuate Therapeutics Inc. (ACTU)")
RSI 14 Market Segment - Cancer cure
Actuate Therapeutics is a clinical-stage biopharmaceutical company developing a new class of oncology drugs targeting the GSK-3 enzyme. This represents a new approach to cancer treatment. This chart reflects the overall sentiment in the oncology sector and helps assess how overheated this speculative biotech segment is.
RSI 14 for the overall market
Actuate (ACTU) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ACTU (Actuate Therapeutics Inc.)
Actuate (ACTU) is a clinical-stage oncology company developing drugs that target the signaling pathways that cancer uses to grow. This chart shows the average target price. It reflects analysts' speculative valuations of this scientific platform and early clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ACTU-Actuate-Therapeutics-Inc.&v=1772661407342 "A chart showing analyst consensus forecasts for the expected stock price. ACTU (Actuate Therapeutics Inc.)")
The difference between the consensus estimate and the actual stock price ACTU (Actuate Therapeutics Inc.)
Actuate Therapeutics is a biotech company developing drugs to treat cancer and inflammatory diseases by targeting novel molecular targets. This chart shows the difference between the market valuation and analyst consensus estimates. It highlights the potential experts see in their early but innovative scientific platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ACTU-Actuate-Therapeutics-Inc.&v=1772661407349 "A chart showing the difference between the consensus forecast and the actual stock price. ACTU (Actuate Therapeutics Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
Actuate Therapeutics is a clinical-stage biotech company developing targeted therapies for cancer (including pancreatic cancer). This chart shows analysts' overall expectations for the oncology sector. It reflects whether experts believe a breakthrough can be achieved in treating the most stubborn cancers.
Analysts' consensus forecast for the overall market share price
Actuate Therapeutics is a clinical-stage oncology biotech developing novel cancer treatments. This is a high-risk R&D company. This chart shows overall market sentiment. For Actuate, as for any non-revenue biotech, it's important to understand how overall risk appetite (sentiment) impacts their ability to raise capital for trials. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Actuate Therapeutics Inc.
Actuate Therapeutics is a clinical-stage biotech company focused on oncology. They are developing a novel drug (a GSK-3 inhibitor) that targets specific signaling pathways responsible for cancer cell growth. This chart is a pure indicator of faith in their science. It doesn't reflect revenue, but rather a speculative estimate of their R&D progress and clinical trial data.
AKIMA Market Segment Index - Cancer cure
Actuate Therapeutics is a clinical-stage oncology company developing drugs that target signaling pathways that enable cancer cells to survive. This chart shows the average index for the cancer treatment sector. It provides a benchmark for how Actuate's performance compares to the sector average for companies exploring new therapeutic pathways.
The AKIM Index for the overall market
Actuate Therapeutics is a biopharmaceutical company developing GSK-3 inhibitors for the treatment of difficult-to-treat cancers. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this clinical-stage research compares to the overall economic trends affecting oncology.
